☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Contact-01 Trial
Exelixis Reports Completion of Patient Enrollment in P-III CONTACT-01 Trial of Cabometyx (cabozantinib) + Tecentriq (atezolizumab)...
November 10, 2021
Load more...
Back to Home
Modal title
×
Modal body text goes here.